Physicians and medical marijuana

American Journal of Psychiatry

Volumn 169, Issue 6, 2012, Pages 564-568

  Kleber, Herbert D ^a,b,c   Dupont, Robert L ^a,b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Institute for Behavior and Health   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; ILLICIT DRUG; NABIXIMOLS;

AMNESIA; ATTENTION DEFICIT DISORDER; CONCENTRATION LOSS; DOSE RESPONSE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDICATION; DRUG LEGISLATION; DRUG POTENCY; DRUG PURIFICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HUMAN; MEDICAL PROFESSION; NOTE; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME;

EID: 84862157712     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12030373     Document Type: Note

References (31)

1. Brett AS, McCullough LB: Addressing requests by patients for nonbeneficial interventions. JAMA 2012; 307:149-150
2. Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, Pritchard A, Robinson G, Beasley R: Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg 2008; 138:374-380 (Pubitemid 351288442)
3. Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S: Association between marijuana exposure and pulmonary function over 20 years. JAMA 2012; 307:173-181
4. Wade DT, Collin C, Stott C, Duncombe P: Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16:707-714
5. Hazekamp A, Grotenhermen F: Review of clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 2010; 5:1-21
6. Zajicek JP, Apostu VI: Role of cannabinoids in multiple sclerosis. CNS Drugs 2011; 25:187-201
7. Rahn EJ, Hohmann AG: Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009; 6:713-737
8. Nunberg H, Kilmer B, Pacula RL, Burgdorft JR: An analysis of applicants presenting to a medical marijuana specialty practice in California. Journal of Drug Policy Analysis 2011; 4:1-16
9. Colorado Department of Public Health and Environment: The Colorado Medical Marijuana Registry: Statistics. Jan 2012. http://www.cdphe.state.co.us/ hs/medicalmarijuana/statistics.html
10. National Research Council: Marijuana and Medicine: Assessing the Science Base. Washington, DC, National Academy Press, 1999
11. National Institute on Drug Abuse: University of Mississippi Potency Monitoring Project. Report 104, March 23, 2009
12. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O'Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK: Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35:764-774
13. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future National Survey Results on Adolescent Drug Use: Overview of Key Findings, 2011. Ann Arbor, Institute for Social Research, The University of Michigan, 2012
14. McCrimmon KK, Mitchell N: Colorado schools see potent influence from nearby medical marijuana sites. Education Week, Feb 6, 2012 (www.edweek.org/ew/ articles/2012/20/06/21enc-marijuana.h31.html)
15. Hall W: The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy 2009; 20:458-466
16. Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:849-863
17. Anthony L, Warner L, Kessler R: Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Study. Clin Exp Psychopharmacol 1994; 2:244-268
18. Substance Abuse and Mental Health Services Administration: Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings: NSDUH Series 11-14. DHHS Publication (SMA) 11-4658. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2011
19. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61:807-816 (Pubitemid 39031120)
20. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW: Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 1999; 141:395-404 (Pubitemid 29190008)
21. Budney AJ, Moore BA: Development and consequences of cannabis dependence. J Clin Pharmacol 2002; 42(11. Suppl):28S-33S
22. Budney AJ, Hughes JR, Moore BA, Vandrey R: Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161:1967-1977 (Pubitemid 39441395)
23. Haney M: The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep 2005; 7:360-366
24. Moore BA, Budney AJ: Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat 2003; 25:85-89 (Pubitemid 37415287)
25. Cerda M, Wall M, Keyes KM, Galea S, Hasin D: Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse, and dependence. Drug Alcohol Depend 2011; 120:22-27
26. Asbridge M, Hayden JA, Cartwright JL: Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344:e536
27. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370:319-328 (Pubitemid 47094993)
28. D'Sousa DC: Cannabinoids and psychosis. Int Rev Neurobiol 2007; 78:849-863
29. Arseneault L, Cannon M, Witton J, Murray RM: Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184:110-117 (Pubitemid 38186851)
30. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM: High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195:488-491
31. Paparelli A, Di Forti M, Morrison PD, Murray RM: Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci 2011; 5:1